MediWound Stock Price, News & Analysis (NASDAQ:MDWD) $9.10 +0.25 (+2.82%) (As of 12/4/2023 ET) Add Compare Share Share Today's Range$8.81▼$9.1050-Day Range$7.58▼$10.8752-Week Range$7.10▼$14.58Volume11,733 shsAverage Volume23,615 shsMarket Capitalization$83.81 millionP/E RatioN/ADividend YieldN/APrice Target$29.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media MediWound MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside218.7% Upside$29.00 Price TargetShort InterestHealthy0.46% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.98Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.96) to ($1.54) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.09 out of 5 starsMedical Sector516th out of 952 stocksMedicinals & Botanicals Industry4th out of 10 stocks 3.5 Analyst's Opinion Consensus RatingMediWound has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $29.00, MediWound has a forecasted upside of 218.7% from its current price of $9.10.Amount of Analyst CoverageMediWound has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.46% of the float of MediWound has been sold short.Short Interest Ratio / Days to CoverMediWound has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MediWound has recently decreased by 20.94%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMediWound does not currently pay a dividend.Dividend GrowthMediWound does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MDWD. Previous Next 3.3 News and Social Media Coverage News SentimentMediWound has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for MediWound this week, compared to 1 article on an average week.Search Interest1 people have searched for MDWD on MarketBeat in the last 30 days. MarketBeat FollowsOnly 2 people have added MediWound to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MediWound insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.20% of the stock of MediWound is held by insiders.Percentage Held by InstitutionsOnly 22.32% of the stock of MediWound is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for MediWound are expected to decrease in the coming year, from ($0.96) to ($1.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MediWound is -5.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MediWound is -5.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMediWound has a P/B Ratio of 6.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About MediWound Stock (NASDAQ:MDWD)MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.Read More MDWD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MDWD Stock News HeadlinesNovember 27, 2023 | finance.yahoo.comDoes MediWound (MDWD) Have the Potential to Rally 223.05% as Wall Street Analysts Expect?November 27, 2023 | americanbankingnews.comAnalysts Set Expectations for MediWound Ltd.'s FY2023 Earnings (NASDAQ:MDWD)December 5, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 24, 2023 | markets.businessinsider.comMediwound’s Promising Outlook: Buy Rating Justified by Q3 Results and Expanding Market OpportunitiesNovember 22, 2023 | markets.businessinsider.comStrong Buy Recommendation for Mediwound: Imminent Drivers, Promising Revenue Stream and Solid Financial FootingNovember 21, 2023 | benzinga.comRecap: MediWound Q3 EarningsNovember 21, 2023 | finance.yahoo.comMediWound Reports Third Quarter 2023 Financial Results and Provides Company UpdateNovember 20, 2023 | msn.comMediWound Q3 2023 Earnings PreviewDecember 5, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 14, 2023 | finance.yahoo.comMediWound to Report Third Quarter 2023 Financial ResultsNovember 13, 2023 | marketwatch.comMediWound Gets CHMP Positive Opinion for NexoBridNovember 13, 2023 | finanznachrichten.deMediWound Ltd.: MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid to Treat Pediatric PatientsNovember 13, 2023 | finance.yahoo.comMediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric PatientsNovember 12, 2023 | morningstar.comMediWound Ltd MDWDNovember 8, 2023 | finance.yahoo.comMediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in EuropeOctober 19, 2023 | finance.yahoo.comMediWound Announces Collaboration with 3M on EscharEx® Phase III StudyOctober 12, 2023 | markets.businessinsider.comMediwound’s Strategic Collaborations and Supply Continuity Drive Buy RecommendationOctober 11, 2023 | markets.businessinsider.comMediWound Partners 3M For Phase III Study Of EscharEx For Leg Ulcer TreatmentOctober 9, 2023 | finance.yahoo.comMediWound Deploys NexoBrid® for Emergency SupplySeptember 29, 2023 | finance.yahoo.comMediWound Ltd. (NASDAQ:MDWD) surges 19%; individual investors who own 46% shares profited along with institutionsSeptember 26, 2023 | finance.yahoo.comMediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. ArmySeptember 22, 2023 | markets.businessinsider.comMaxim Group Sticks to Their Buy Rating for Mediwound (MDWD)September 21, 2023 | msn.comMediWound burn therapy NexoBrid launched in USSeptember 21, 2023 | markets.businessinsider.comHC Wainwright & Co. Maintains Buy Rating for MediWound: Here's What You Need To KnowSeptember 21, 2023 | markets.businessinsider.comMediWound Announces Full Commercial Launch Of NexoBrid - Quick FactsSeptember 21, 2023 | finance.yahoo.comMediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in AdultsSeptember 11, 2023 | markets.businessinsider.comMediWound’s NexoBrid® Highlighted in 20 Oral and Poster Presentations at the 20th European Burns Association CongressSee More Headlines Receive MDWD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MediWound and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/21/2023Today12/05/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medicinals & botanicals Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MDWD CUSIPN/A CIK1593984 Webwww.mediwound.com Phone972779714100Fax972-77-971-4111Employees83Year Founded2001Price Target and Rating Average Stock Price Target$29.00 High Stock Price Target$36.00 Low Stock Price Target$25.00 Potential Upside/Downside+218.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,600,000.00 Net Margins-49.79% Pretax Margin-49.27% Return on Equity-44.32% Return on Assets-19.88% Debt Debt-to-Equity RatioN/A Current Ratio6.31 Quick Ratio5.88 Sales & Book Value Annual Sales$26.50 million Price / Sales3.16 Cash FlowN/A Price / Cash FlowN/A Book Value$1.51 per share Price / Book6.03Miscellaneous Outstanding Shares9,210,000Free Float8,359,000Market Cap$83.81 million OptionableNot Optionable Beta1.05 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Ofer Gonen B.Sc. (Age 50)Chief Executive Officer Comp: $485kDr. Lior Rosenberg M.D. (Age 77)Co-Founder Comp: $727kDr. Ety Klinger MBA (Age 61)Ph.D., Chief Research & Development Officer Comp: $393kMs. Hani LuxenburgChief Financial OfficerMr. Tzvi Palash B.Sc. (Age 66)M.Sc., Chief Operating Officer Mr. Yaron Meyer Adv. (Age 44)Executive VP, General Counsel & Corporate Secretary Comp: $240kMr. Barry J. Wolfenson (Age 56)Executive Vice President of Strategy & Corporate Development Dr. Robert J. Snyder CWS (Age 73)D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc., Chief Medical Officer More ExecutivesKey CompetitorsFitLife BrandsNASDAQ:FTLFBright GreenNASDAQ:BGXXChromaDexNASDAQ:CDXCMind Medicine (MindMed)NASDAQ:MNMDNatural Alternatives InternationalNASDAQ:NAIIView All CompetitorsInstitutional OwnershipEssex Investment Management Co. LLCSold 3,024 shares on 11/9/2023Ownership: 0.574%Yelin Lapidot Holdings Management Ltd.Bought 86,145 shares on 10/30/2023Ownership: 0.935%View All Institutional Transactions MDWD Stock Analysis - Frequently Asked Questions Should I buy or sell MediWound stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MediWound in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MDWD shares. View MDWD analyst ratings or view top-rated stocks. What is MediWound's stock price target for 2024? 4 analysts have issued 1 year target prices for MediWound's stock. Their MDWD share price targets range from $25.00 to $36.00. On average, they expect the company's stock price to reach $29.00 in the next twelve months. This suggests a possible upside of 218.7% from the stock's current price. View analysts price targets for MDWD or view top-rated stocks among Wall Street analysts. How have MDWD shares performed in 2023? MediWound's stock was trading at $13.49 at the beginning of 2023. Since then, MDWD shares have decreased by 32.5% and is now trading at $9.10. View the best growth stocks for 2023 here. Are investors shorting MediWound? MediWound saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 30,200 shares, a decline of 20.9% from the October 31st total of 38,200 shares. Based on an average daily trading volume, of 23,000 shares, the short-interest ratio is presently 1.3 days. Approximately 0.5% of the company's stock are short sold. View MediWound's Short Interest. When is MediWound's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our MDWD earnings forecast. How were MediWound's earnings last quarter? MediWound Ltd. (NASDAQ:MDWD) announced its quarterly earnings data on Tuesday, November, 21st. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.21. The biopharmaceutical company had revenue of $4.78 million for the quarter, compared to the consensus estimate of $4.73 million. MediWound had a negative trailing twelve-month return on equity of 44.32% and a negative net margin of 49.79%. During the same quarter last year, the firm earned ($0.91) EPS. When did MediWound's stock split? MediWound's stock reverse split on Tuesday, December 20th 2022. The 1-7 reverse split was announced on Tuesday, December 20th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. What other stocks do shareholders of MediWound own? Based on aggregate information from My MarketBeat watchlists, some companies that other MediWound investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), Blackstone (BX), Dynavax Technologies (DVAX), Geron (GERN), Idera Pharmaceuticals (IDRA), Mastercard (MA), SCYNEXIS (SCYX), Vascular Biogenics (VBLT) and Wells Fargo & Company (WFC). Who are MediWound's major shareholders? MediWound's stock is owned by a variety of retail and institutional investors. Top institutional investors include Yelin Lapidot Holdings Management Ltd. (0.94%), Essex Investment Management Co. LLC (0.57%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of MediWound? Shares of MDWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:MDWD) was last updated on 12/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediWound Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.